Barclays’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-696,710
| Closed | -$16.7M | – | 5204 |
|
|
2021
Q1 | $16.7M | Buy |
696,710
+672,340
| +2,759% | +$12.5M | 0.01% | 867 |
|
|
2020
Q4 | $355K | Sell |
24,370
-7,778
| -24% | -$103K | ﹤0.01% | 3452 |
|
|
2020
Q3 | $456K | Sell |
32,148
-5,130
| -14% | -$78.4K | ﹤0.01% | 3297 |
|
|
2020
Q2 | $548K | Sell |
37,278
-1,741
| -4% | -$17.7K | ﹤0.01% | 3272 |
|
|
2020
Q1 | $161K | Sell |
39,019
-68,497
| -64% | -$321K | ﹤0.01% | 4463 |
|
|
2019
Q4 | $517K | Buy |
107,516
+40,787
| +61% | +$225K | ﹤0.01% | 4279 |
|
|
2019
Q3 | $404K | Buy |
66,729
+11,330
| +20% | +$70.7K | ﹤0.01% | 4414 |
|
|
2019
Q2 | $359K | Buy |
55,399
+40,650
| +276% | +$286K | ﹤0.01% | 4617 |
|
|
2019
Q1 | $105K | Buy |
+14,749
| New | +$97.1K | ﹤0.01% | 5324 |
|
|
2018
Q4 | – | Sell |
-20,561
| Closed | -$151K | – | 7563 |
|
|
2018
Q3 | $151K | Buy |
20,561
+14,192
| +223% | +$104K | ﹤0.01% | 5217 |
|
|
2018
Q2 | $40K | Sell |
6,369
-4,249
| -40% | -$28.1K | ﹤0.01% | 5781 |
|
|
2018
Q1 | $58K | Buy |
10,618
+2,532
| +31% | +$12.6K | ﹤0.01% | 5808 |
|
|
2017
Q4 | $34K | Buy |
8,086
+6,905
| +585% | +$41.6K | ﹤0.01% | 5989 |
|
|
2017
Q3 | $11K | Buy |
1,181
+1,148
| +3,479% | +$11.9K | ﹤0.01% | 6102 |
|
|
2017
Q2 | $0 | Sell |
33
-1,943
| -98% | -$24.8K | ﹤0.01% | 7080 |
|
|
2017
Q1 | $25K | Sell |
1,976
-997
| -34% | -$12K | ﹤0.01% | 5714 |
|
|
2016
Q4 | $36K | Buy |
2,973
+2,416
| +434% | +$28.7K | ﹤0.01% | 5354 |
|
|
2016
Q3 | $7K | Buy |
557
+496
| +813% | +$4.79K | ﹤0.01% | 5929 |
|
|
2016
Q2 | $1K | Sell |
61
-1,776
| -97% | -$12.2K | ﹤0.01% | 6206 |
|
|
2016
Q1 | $9K | Buy |
+1,837
| New | +$10.2K | ﹤0.01% | 5519 |
|
|
2015
Q4 | – | Sell |
-1,442
| Closed | -$11K | – | 6814 |
|
|
2015
Q3 | $11K | Buy |
1,442
+636
| +79% | +$5.88K | ﹤0.01% | 5752 |
|
|
2015
Q2 | $7K | Sell |
806
-447
| -36% | -$4.51K | ﹤0.01% | 6300 |
|
|
2015
Q1 | $15K | Sell |
1,253
-5,917
| -83% | -$77.4K | ﹤0.01% | 5999 |
|
|
2014
Q4 | $93K | Buy |
7,170
+5,734
| +399% | +$64.1K | ﹤0.01% | 5269 |
|
|
2014
Q3 | $11K | Sell |
1,436
-914
| -39% | -$9.84K | ﹤0.01% | 6846 |
|
|
2014
Q2 | $31K | Buy |
2,350
+942
| +67% | +$9.83K | ﹤0.01% | 6275 |
|
|
2014
Q1 | $13K | Sell |
1,408
-529
| -27% | -$6.57K | ﹤0.01% | 6817 |
|
|
2013
Q4 | $25K | Buy |
1,937
+520
| +37% | +$6.32K | ﹤0.01% | 6588 |
|
|
2013
Q3 | $17K | Sell |
1,417
-113
| -7% | -$1.21K | ﹤0.01% | 6598 |
|
|
2013
Q2 | $16K | Buy |
+1,530
| New | +$21.1K | ﹤0.01% | 6943 |
|
Barclays's GNMK Position: Q2 2021 in Review
Barclays sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 696,710 shares — an estimated $16.7M sold.
Barclays first reported a position in GNMK in Q2 2013 and held it in 30 quarters. The position peaked at $16.7M in Q1 2021. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- Barclays reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- Barclays sold 696,710 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $16.7M.
- Barclays first reported a position in GenMark Diagnostics, Inc in Q2 2013 and held it in 30 quarters.
- Barclays's GenMark Diagnostics, Inc position peaked at $16.7M in Q1 2021.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on Barclays's 13F filing for Q2 2021, filed 13 Aug 2021.